Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of olverembatinib in chronic-phase CML after resistance or intolerance to one prior TKI
ChiCTR2200061655Phase 2Not yet recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olverembatinib in chronic myelogenous leukemia (CML), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoint: Complete cytogenetic response rate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
olverembatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR2200061655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061655.